Thinking Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty in Cost-Effectiveness Studies
Top Cited Papers
- 1 May 2002
- journal article
- review article
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 23 (1) , 377-401
- https://doi.org/10.1146/annurev.publhealth.23.100901.140534
Abstract
▪ Abstract As many more clinical trials collect economic information within their study design, so health economics analysts are increasingly working with patient-level data on both costs and effects. In this paper, we review recent advances in the use of statistical methods for economic analysis of information collected alongside clinical trials. In particular, we focus on the handling and presentation of uncertainty, including the importance of estimation rather than hypothesis testing, the use of the net-benefit statistic, and the presentation of cost-effectiveness acceptability curves. We also discuss the appropriate sample size calculations for cost-effectiveness analysis at the design stage of a study. Finally, we outline some of the challenges for future research in this area—particularly in relation to the appropriate use of Bayesian methods and methods for analyzing costs that are typically skewed and often incomplete.Keywords
This publication has 52 references indexed in Scilit:
- The Importance of the Normality Assumption in Large Public Health Data SetsAnnual Review of Public Health, 2002
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002
- ECONOMIC EVALUATION OF DIAGNOSTIC TESTSInternational Journal of Technology Assessment in Health Care, 1999
- Sequence Effects, Health Profiles, and the QALY ModelMedical Decision Making, 1998
- An economic approach to clinical trial design and research priority-settingHealth Economics, 1996
- Confidence intervals for cost-effectiveness ratios: An application of Fieller's theoremHealth Economics, 1996
- Modelling programme costs in economic evaluationJournal of Health Economics, 1996
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Statistical Versus Quantitative Significance in the Socioeconomic Evaluation of MedicinesPharmacoEconomics, 1994
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978